Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Second Line Therapy and Beyond With Relacorilant and Nab-Paclitaxel for Cervical Cancer With Loss of Benefit From Immune Checkpoint and Platinum Exposure

NCT07763496 is registered in ClinicalTrials.gov with ARCAGY/ GINECO GROUP as lead sponsor.

NCT NCT07763496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07763496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Second Line Therapy and Beyond With Relacorilant and Nab-Paclitaxel for Cervical Cancer With Loss of Benefit From Immune Checkpoint and Platinum Exposure
Lead sponsor
ARCAGY/ GINECO GROUP
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
December 31, 2030
Enrollment
63 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic cervical cancer